EIF2AK3 and hepatocellular carcinoma: A biomarker companion study (BIOSTORM), using tissues from phase 3 STORM trial on HCC patients treated with sorafenib or placebo, revealed that only pERK and microvascular invasion served as independent prognostic factors for poor recurrence-free survival (RFS) in sorafenib-treated patients [44].